Christopher Jewell - Jan 2, 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Chief Scientific Officer
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Christopher Jewell
Stock symbol
RNAC
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 05:08 PM
Previous filing
Nov 15, 2023
Next filing
Apr 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Award $0 +778K $0.00 778K Jan 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Employee Stock Option (right to buy) Award $0 +998K $0.00 998K Jan 2, 2024 Common Stock 998K $0.66 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.
F2 This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.

Remarks:

Exhibit 24 - Power of Attorney